HUTCHMED’s savolitinib-simertinib combo shows landmark survival data in The Lancet
HUTCHMED (China) (NASDAQ:HCM) and partner AstraZeneca (NYSE:AZN) reached a major scientific milestone Wednesday with the publication of full Phase III SACHI trial results in The Lancet.







-640x358.jpg&w=3840&q=75)





-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)

-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)

-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)